Apogee Therapeutics, Inc. Common Stock
APGEApogee Therapeutics, Inc. (APGE) is a biopharmaceutical company focused on the development of targeted therapies for immune-mediated diseases. The company's pipeline emphasizes innovative treatments aimed at improving patient outcomes in areas such as inflammatory and autoimmune disorders.
Company News
Halper Sadeh LLC, an investor rights law firm, is investigating four companies for potential securities law violations and breaches of fiduciary duties related to their proposed mergers and acquisitions. The firm is examining whether shareholders are receiving fair consideration and whether insider benefits may be limiting superior competing offe...
Apogee Therapeutics CEO Michael Henderson disposed of 95,046 shares, with 75,046 gifted to charity and 20,000 sold under a pre-established trading plan. Henderson retains 921,000 shares worth ~$123 million. The insider activity is not viewed as a red flag given the CEO's substantial remaining stake. Apogee's lead antibody candidate showed strong ...
AbbVie, a Dividend King, is acquiring Apogee Therapeutics for $10.9 billion to strengthen its drug pipeline and maintain its dividend growth streak. The deal brings late-stage drug candidates like zumilokibart for atopic dermatitis and respiratory drugs, helping AbbVie replace revenue lost from Humira's patent expiration with newer products like ...
Investor rights law firm Halper Sadeh LLC is investigating four companies for potential securities law violations and breaches of fiduciary duties related to their proposed acquisitions. The firm is examining whether shareholders are receiving fair consideration and whether insider benefits may be limiting competing offers.
AbbVie announced a $10.9 billion acquisition of clinical-stage biotech Apogee Therapeutics, paying $135.11 per share in cash. The deal strengthens AbbVie's immunology portfolio with access to promising drug candidates like zumilokibart for eczema and asthma. While the acquisition will create near-term EPS headwinds, analysts expect it to be accre...
